Michele Fox
Concepts (268)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cells | 9 | 2025 | 187 | 1.630 |
Why?
| Hematopoietic Stem Cell Transplantation | 14 | 2025 | 603 | 1.540 |
Why?
| Hematopoietic Stem Cell Mobilization | 11 | 2018 | 60 | 1.440 |
Why?
| Multiple Myeloma | 27 | 2025 | 3049 | 1.400 |
Why?
| Blood Component Removal | 5 | 2025 | 15 | 1.000 |
Why?
| Antigens, CD34 | 10 | 2025 | 72 | 0.850 |
Why?
| Blood Platelets | 5 | 2017 | 259 | 0.780 |
Why?
| Leukapheresis | 4 | 2025 | 19 | 0.670 |
Why?
| Melphalan | 4 | 2016 | 181 | 0.550 |
Why?
| Bone Marrow Transplantation | 4 | 2016 | 113 | 0.530 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 2 | 2018 | 14 | 0.520 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1031 | 0.510 |
Why?
| Plasma Exchange | 3 | 2015 | 25 | 0.480 |
Why?
| Transplantation, Autologous | 9 | 2025 | 488 | 0.440 |
Why?
| Fetal Blood | 3 | 2023 | 80 | 0.440 |
Why?
| Cell Separation | 2 | 2013 | 83 | 0.400 |
Why?
| Pregnant Women | 1 | 2023 | 70 | 0.390 |
Why?
| Killer Cells, Natural | 2 | 2015 | 116 | 0.360 |
Why?
| Humans | 44 | 2025 | 52483 | 0.340 |
Why?
| Cell Proliferation | 5 | 2018 | 1023 | 0.340 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 166 | 0.330 |
Why?
| Myelodysplastic Syndromes | 2 | 2013 | 86 | 0.330 |
Why?
| Granulocyte Colony-Stimulating Factor | 4 | 2012 | 64 | 0.330 |
Why?
| Blood Transfusion | 2 | 2017 | 127 | 0.310 |
Why?
| Thalidomide | 4 | 2016 | 377 | 0.310 |
Why?
| Blood Specimen Collection | 1 | 2019 | 35 | 0.310 |
Why?
| Blood Volume | 1 | 2019 | 66 | 0.310 |
Why?
| Education, Distance | 1 | 2019 | 42 | 0.300 |
Why?
| Adult | 22 | 2019 | 14161 | 0.290 |
Why?
| Aged | 21 | 2017 | 10121 | 0.290 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 28 | 0.290 |
Why?
| Cryopreservation | 2 | 2025 | 41 | 0.290 |
Why?
| Obstetrics | 1 | 2019 | 89 | 0.280 |
Why?
| Leukocytes, Mononuclear | 1 | 2018 | 123 | 0.280 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2017 | 39 | 0.280 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 5 | 0.280 |
Why?
| Blood Coagulation | 1 | 2017 | 64 | 0.270 |
Why?
| Chromosome Aberrations | 3 | 2016 | 297 | 0.270 |
Why?
| Middle Aged | 21 | 2018 | 13028 | 0.260 |
Why?
| Flow Cytometry | 2 | 2016 | 478 | 0.260 |
Why?
| Aspirin | 1 | 2017 | 115 | 0.260 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 122 | 0.260 |
Why?
| Antibodies | 1 | 2016 | 159 | 0.250 |
Why?
| Erythrocyte Transfusion | 2 | 2015 | 52 | 0.250 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 181 | 0.250 |
Why?
| Heparin | 1 | 2015 | 88 | 0.240 |
Why?
| Hemoglobins, Abnormal | 1 | 2015 | 4 | 0.240 |
Why?
| Female | 22 | 2023 | 28171 | 0.230 |
Why?
| Thrombocytopenia | 1 | 2015 | 89 | 0.230 |
Why?
| Stem Cell Transplantation | 2 | 2013 | 185 | 0.230 |
Why?
| Factor VIII | 1 | 2014 | 23 | 0.230 |
Why?
| ADAM Proteins | 1 | 2014 | 20 | 0.220 |
Why?
| Leukocytes | 2 | 2011 | 66 | 0.220 |
Why?
| Retrospective Studies | 9 | 2025 | 6607 | 0.220 |
Why?
| Internship and Residency | 1 | 2019 | 448 | 0.210 |
Why?
| Anemia, Sickle Cell | 1 | 2015 | 106 | 0.210 |
Why?
| Follow-Up Studies | 8 | 2024 | 2279 | 0.210 |
Why?
| Male | 21 | 2019 | 26761 | 0.210 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 32 | 0.200 |
Why?
| Leukemia | 1 | 2013 | 67 | 0.200 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.200 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 649 | 0.200 |
Why?
| Graft Survival | 4 | 2011 | 160 | 0.200 |
Why?
| Aldehyde Dehydrogenase | 1 | 2011 | 25 | 0.190 |
Why?
| Prognosis | 6 | 2018 | 2099 | 0.190 |
Why?
| Transplantation Conditioning | 3 | 2003 | 93 | 0.180 |
Why?
| Boronic Acids | 2 | 2013 | 183 | 0.180 |
Why?
| Pyrazines | 2 | 2013 | 190 | 0.180 |
Why?
| Plateletpheresis | 1 | 2010 | 7 | 0.180 |
Why?
| Blood Preservation | 1 | 2010 | 27 | 0.170 |
Why?
| Transplantation, Homologous | 5 | 2016 | 150 | 0.170 |
Why?
| Blood Proteins | 1 | 2010 | 85 | 0.170 |
Why?
| Anaphylaxis | 1 | 2010 | 69 | 0.170 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2007 | 96 | 0.160 |
Why?
| Cell Survival | 5 | 2011 | 612 | 0.160 |
Why?
| Graft vs Host Disease | 5 | 2003 | 87 | 0.150 |
Why?
| Receptors, KIR | 1 | 2008 | 12 | 0.150 |
Why?
| HIV Infections | 1 | 2013 | 389 | 0.150 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 857 | 0.150 |
Why?
| Myeloablative Agonists | 1 | 2007 | 32 | 0.140 |
Why?
| Cell Movement | 2 | 2006 | 268 | 0.140 |
Why?
| Immunosuppressive Agents | 2 | 2014 | 243 | 0.140 |
Why?
| Treatment Outcome | 11 | 2013 | 5422 | 0.140 |
Why?
| Dexamethasone | 3 | 2024 | 438 | 0.130 |
Why?
| Risk Factors | 7 | 2015 | 3889 | 0.130 |
Why?
| Models, Genetic | 1 | 2006 | 169 | 0.130 |
Why?
| Osteogenesis | 2 | 2006 | 366 | 0.130 |
Why?
| Models, Statistical | 1 | 2007 | 230 | 0.120 |
Why?
| Young Adult | 4 | 2019 | 4329 | 0.120 |
Why?
| Combined Modality Therapy | 4 | 2014 | 639 | 0.120 |
Why?
| Cytokines | 2 | 2006 | 623 | 0.120 |
Why?
| Platelet Count | 3 | 2017 | 75 | 0.120 |
Why?
| Macrophages | 1 | 2018 | 379 | 0.120 |
Why?
| Gene Expression Profiling | 2 | 2007 | 1105 | 0.120 |
Why?
| Incidence | 3 | 2017 | 1062 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 235 | 0.120 |
Why?
| Time Factors | 1 | 2010 | 2968 | 0.110 |
Why?
| Antineoplastic Agents | 3 | 2012 | 1222 | 0.110 |
Why?
| Pregnancy | 2 | 2023 | 2680 | 0.110 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 2016 | 26 | 0.110 |
Why?
| Disease-Free Survival | 3 | 2016 | 460 | 0.100 |
Why?
| Blood Banks | 1 | 2023 | 18 | 0.100 |
Why?
| Bone Marrow Cells | 1 | 2004 | 190 | 0.100 |
Why?
| Metaphase | 2 | 2016 | 46 | 0.100 |
Why?
| Bone Diseases | 1 | 2004 | 96 | 0.100 |
Why?
| Cell Count | 3 | 2011 | 149 | 0.100 |
Why?
| Osteoblasts | 1 | 2006 | 475 | 0.100 |
Why?
| Cyclosporine | 1 | 2003 | 67 | 0.100 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 4 | 0.100 |
Why?
| Tacrolimus | 1 | 2003 | 59 | 0.100 |
Why?
| ABO Blood-Group System | 1 | 2002 | 15 | 0.100 |
Why?
| Universities | 1 | 2023 | 175 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2007 | 483 | 0.090 |
Why?
| Coculture Techniques | 3 | 2018 | 144 | 0.090 |
Why?
| Osteoclasts | 1 | 2004 | 428 | 0.090 |
Why?
| T-Lymphocyte Subsets | 1 | 2001 | 41 | 0.090 |
Why?
| Models, Biological | 1 | 2004 | 735 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 66 | 0.080 |
Why?
| Lung Diseases | 1 | 2001 | 88 | 0.080 |
Why?
| Prospective Studies | 4 | 2016 | 2481 | 0.080 |
Why?
| Thrombosis | 1 | 2003 | 253 | 0.080 |
Why?
| Heart Failure | 1 | 2006 | 565 | 0.080 |
Why?
| Cancer Vaccines | 1 | 2010 | 78 | 0.080 |
Why?
| Dendritic Cells | 1 | 2010 | 136 | 0.080 |
Why?
| Erythroid Precursor Cells | 1 | 2019 | 15 | 0.080 |
Why?
| Birth Weight | 1 | 2019 | 125 | 0.070 |
Why?
| Hematocrit | 1 | 2018 | 44 | 0.070 |
Why?
| Cell Aggregation | 1 | 2017 | 5 | 0.070 |
Why?
| Medical Waste | 1 | 2017 | 3 | 0.070 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2008 | 77 | 0.070 |
Why?
| Lymphoma | 1 | 2018 | 71 | 0.070 |
Why?
| Program Evaluation | 1 | 2019 | 353 | 0.070 |
Why?
| Arkansas | 2 | 2017 | 2028 | 0.070 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 27 | 0.070 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 48 | 0.070 |
Why?
| Logistic Models | 2 | 2017 | 925 | 0.070 |
Why?
| Lung | 1 | 2001 | 509 | 0.070 |
Why?
| Adolescent | 3 | 2015 | 6739 | 0.070 |
Why?
| Risk | 1 | 2017 | 316 | 0.070 |
Why?
| Neoplasms | 1 | 2007 | 1325 | 0.070 |
Why?
| Fibrosis | 1 | 2017 | 196 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1378 | 0.060 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 106 | 0.060 |
Why?
| Curriculum | 1 | 2019 | 398 | 0.060 |
Why?
| Recurrence | 2 | 2008 | 672 | 0.060 |
Why?
| Hemorrhage | 1 | 2017 | 209 | 0.060 |
Why?
| Hemoglobin J | 1 | 2015 | 3 | 0.060 |
Why?
| Hemoglobin, Sickle | 1 | 2015 | 6 | 0.060 |
Why?
| Hemoglobin C | 1 | 2015 | 6 | 0.060 |
Why?
| Blood Donors | 1 | 2015 | 21 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1046 | 0.060 |
Why?
| Neoplasm Proteins | 1 | 2016 | 334 | 0.060 |
Why?
| Reproducibility of Results | 1 | 2017 | 1229 | 0.050 |
Why?
| Age Factors | 3 | 2005 | 1132 | 0.050 |
Why?
| Autoantibodies | 1 | 2014 | 121 | 0.050 |
Why?
| Blotting, Western | 1 | 2015 | 590 | 0.050 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 33 | 0.050 |
Why?
| Viral Load | 1 | 2013 | 82 | 0.050 |
Why?
| Transplantation Chimera | 3 | 2003 | 16 | 0.050 |
Why?
| Acute Disease | 1 | 2013 | 373 | 0.050 |
Why?
| Benzylamines | 1 | 2012 | 14 | 0.050 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 29 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2015 | 979 | 0.050 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 52 | 0.050 |
Why?
| Heterocyclic Compounds | 1 | 2012 | 28 | 0.050 |
Why?
| Infant, Newborn | 1 | 2019 | 2867 | 0.050 |
Why?
| Clinical Protocols | 1 | 2012 | 108 | 0.050 |
Why?
| Immune Tolerance | 1 | 2011 | 91 | 0.050 |
Why?
| Dimethyl Sulfoxide | 1 | 2010 | 12 | 0.040 |
Why?
| Isotonic Solutions | 1 | 2010 | 20 | 0.040 |
Why?
| Platelet Transfusion | 1 | 2010 | 33 | 0.040 |
Why?
| P-Selectin | 1 | 2010 | 30 | 0.040 |
Why?
| Sodium Chloride | 1 | 2010 | 56 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2010 | 72 | 0.040 |
Why?
| Platelet Activation | 1 | 2010 | 47 | 0.040 |
Why?
| Algorithms | 2 | 2005 | 672 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2007 | 591 | 0.040 |
Why?
| Feasibility Studies | 1 | 2011 | 406 | 0.040 |
Why?
| Hypersensitivity | 1 | 2010 | 81 | 0.040 |
Why?
| Haplotypes | 1 | 2008 | 92 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 62 | 0.040 |
Why?
| Ligands | 1 | 2008 | 206 | 0.040 |
Why?
| Arginase | 1 | 2018 | 38 | 0.040 |
Why?
| Polyethylene Glycols | 1 | 2008 | 90 | 0.040 |
Why?
| Hemoglobins | 1 | 2008 | 112 | 0.040 |
Why?
| Age Distribution | 1 | 2007 | 174 | 0.030 |
Why?
| Cytogenetic Analysis | 1 | 2007 | 80 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2008 | 483 | 0.030 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 53 | 0.030 |
Why?
| Multigene Family | 1 | 2006 | 48 | 0.030 |
Why?
| Tissue Donors | 2 | 2003 | 126 | 0.030 |
Why?
| Mice | 2 | 2018 | 5949 | 0.030 |
Why?
| Chromosome Deletion | 1 | 2007 | 142 | 0.030 |
Why?
| Chromosome Mapping | 1 | 2006 | 154 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2007 | 263 | 0.030 |
Why?
| Angiogenesis Inhibitors | 1 | 2007 | 183 | 0.030 |
Why?
| Cell Line | 1 | 2008 | 1030 | 0.030 |
Why?
| Interleukin-10 | 1 | 2006 | 84 | 0.030 |
Why?
| Cell Communication | 1 | 2006 | 71 | 0.030 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 203 | 0.030 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 114 | 0.030 |
Why?
| Stroke Volume | 1 | 2006 | 155 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2007 | 944 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2006 | 121 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2006 | 108 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2006 | 552 | 0.030 |
Why?
| Bromodeoxyuridine | 1 | 2004 | 19 | 0.030 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 33 | 0.030 |
Why?
| Annexin A5 | 1 | 2004 | 14 | 0.030 |
Why?
| Databases, Factual | 1 | 2007 | 706 | 0.030 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 47 | 0.030 |
Why?
| Survival Rate | 1 | 2006 | 945 | 0.030 |
Why?
| Phagocytosis | 1 | 2004 | 53 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2006 | 399 | 0.030 |
Why?
| Chronic Disease | 1 | 2006 | 586 | 0.030 |
Why?
| Cell Division | 1 | 2004 | 291 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2006 | 3392 | 0.030 |
Why?
| Plasmapheresis | 1 | 2003 | 12 | 0.030 |
Why?
| RANK Ligand | 1 | 2004 | 187 | 0.020 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 244 | 0.020 |
Why?
| Interleukin-6 | 1 | 2004 | 278 | 0.020 |
Why?
| Salvage Therapy | 2 | 2003 | 136 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2006 | 1026 | 0.020 |
Why?
| NF-kappa B | 1 | 2004 | 322 | 0.020 |
Why?
| Cohort Studies | 1 | 2006 | 1542 | 0.020 |
Why?
| Carrier Proteins | 1 | 2004 | 313 | 0.020 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.020 |
Why?
| Child | 1 | 2015 | 7248 | 0.020 |
Why?
| Animals | 2 | 2018 | 13505 | 0.020 |
Why?
| Antigens, CD | 1 | 2003 | 218 | 0.020 |
Why?
| Survival Analysis | 2 | 2003 | 673 | 0.020 |
Why?
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 2 | 0.020 |
Why?
| Cell Differentiation | 1 | 2004 | 665 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2001 | 20 | 0.020 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2001 | 40 | 0.020 |
Why?
| Clone Cells | 1 | 2001 | 77 | 0.020 |
Why?
| Graft Rejection | 1 | 2002 | 177 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 18 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2006 | 1478 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 15 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 44 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 64 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 52 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2001 | 132 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1546 | 0.020 |
Why?
| Interferon-gamma | 1 | 2010 | 180 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 582 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2001 | 164 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2001 | 378 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2010 | 184 | 0.020 |
Why?
| Vaccination | 1 | 2010 | 298 | 0.020 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 158 | 0.010 |
Why?
| Probability | 1 | 2003 | 172 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 73 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 2003 | 220 | 0.010 |
Why?
| Cyclophosphamide | 1 | 2003 | 171 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2003 | 374 | 0.010 |
Why?
| Remission Induction | 1 | 2003 | 218 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 451 | 0.010 |
Why?
| Neutrophils | 1 | 2003 | 147 | 0.010 |
Why?
| Doxorubicin | 1 | 2003 | 241 | 0.010 |
Why?
| Cisplatin | 1 | 2003 | 285 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2003 | 772 | 0.010 |
Why?
| Drug Resistance, Neoplasm | 1 | 2003 | 326 | 0.010 |
Why?
| Disease Progression | 1 | 2003 | 871 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|